![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Abits
ABTS
Digihost Technology
DGHI
Argo Blockchain
ARBK
FRMO CORP
FRMO
The9 Ltd
NCTY
US Stock MarketDetailed Quotes
ALMS Alumis
- 4.480
- +0.150+3.46%
Close Mar 18 16:00 ET
- 4.480
- 0.0000.00%
Post 16:05 ET
243.74MMarket Cap-1.02P/E (TTM)
4.548High4.250Low112.50KVolume4.360Open4.330Pre Close496.34KTurnover0.46%Turnover RatioLossP/E (Static)54.41MShares13.53052wk High0.70P/B108.91MFloat Cap4.25052wk Low--Dividend TTM24.31MShs Float13.530Historical High--Div YieldTTM6.89%Amplitude4.250Historical Low4.412Avg Price1Lot Size
Alumis Stock Forum
Sign in to post a comment
$Alumis (ALMS.US)$
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
Positive
Sustained or increasing efficacy at 52 weeks with PASI 90 reaching 61.3%
Strong quality of life improvements with 81.3% itch control
Well-tolerated safety profile with no new concerns at 52 weeks
Phase 3 trial progression on track with clear timeline
Negative
Phase 3 results not expected until Q1 2026, indicating lengthy time to ...
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
Positive
Sustained or increasing efficacy at 52 weeks with PASI 90 reaching 61.3%
Strong quality of life improvements with 81.3% itch control
Well-tolerated safety profile with no new concerns at 52 weeks
Phase 3 trial progression on track with clear timeline
Negative
Phase 3 results not expected until Q1 2026, indicating lengthy time to ...
2
2
$Alumis (ALMS.US)$
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
Saturday, 8th March at 9:00 am
• ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus
• Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90...
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
Saturday, 8th March at 9:00 am
• ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus
• Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90...
2
$Alumis (ALMS.US)$
New Psoriasis Drug Maintains Remarkable 61% Skin Clearance After One Year - Key Trial Results
New Psoriasis Drug Maintains Remarkable 61% Skin Clearance After One Year - Key Trial Results
$Alumis (ALMS.US)$ $Acelyrin (SLRN.US)$
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
1
$Alumis (ALMS.US)$
Can Alumis's Fast-Tracked Psoriasis Drug Challenge Market Leaders? Phase 3 Timeline Speeds Up
Can Alumis's Fast-Tracked Psoriasis Drug Challenge Market Leaders? Phase 3 Timeline Speeds Up
$Alumis (ALMS.US)$
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Friday, 28th February at 9:08 am
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis –
– Additional Phase 2 e-poster presentations to describe patient-reported outcomes,...
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Friday, 28th February at 9:08 am
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis –
– Additional Phase 2 e-poster presentations to describe patient-reported outcomes,...
2
$Alumis (ALMS.US)$
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Thursday, 27th February at 4:15 pm
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ: ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ou...
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Thursday, 27th February at 4:15 pm
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ: ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ou...
1
$Alumis (ALMS.US)$ $Acelyrin (SLRN.US)$
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
59
8
4
$Alumis (ALMS.US)$ is this a drop that is expected to bounce back after merger confirmation?
1
No comment yet
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Ezkilz : which ones are you betting on
This_Guy OP Ezkilz : none right now. I actually don't have my usual pick going into Monday. Not yet anyway. maybe will just see what happens as the morning unfolds into regular hours. Kind of hoping we get a killer PR from a company that's a no brainer and just ride it. There is ICON which i traded Friday but most know about it. It's got some hype around it so maybe Monday will be its day to run.